The role of sentinel lymph node biopsy (SLNB) in soft tissue sarcoma patients has yet to be determined. We sought to evaluate the role of SLNB in the treatment of patients with clear cell sarcoma (CCS), synovial sarcoma (SS), epithelioid sarcoma (ES) and rhabdomyosarcoma (RMS).

Sixty-two consecutive patients without history of regional lymphatic spread or evidence of distant metastases underwent SLNB.

Positive sentinel nodes were identified in 2 out of 42 patients with SS and in 6 out of 12 patients with CCS. Only two CCS patients had further metastatic nodes in regional dissection. Both of these patients, along with another CCS patient, developed distant metastases and ultimately died of disease. The remaining three CCS patients are disease-free in follow-up. One patient with SS and another with ES developed regional lymph node metastases following a negative SLNB, while a further patient with RMS developed distant metastases followed by a local recurrence with regional metastases shortly after.

SLNB is an important diagnostic tool for patients with CCS, who appear to have a high rate of clinically occult regional lymph node metastases at diagnosis. For SS patients, SLNB appears to be of very little relevance.

Polls results

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
100% Article relates to my practice (1/1)
0% Article does not relate to my practice (0/1)
0% Undecided (0/1)

Will this article lead to more cost-effective healthcare?

0% Yes (0/1)
100% No (1/1)
0% Undecided (0/1)

Was this article biased? (commercial or personal)

0% Yes (0/1)
100% No (1/1)
0% Undecided (0/1)

What level of evidence do you think this article is?

0% Level 1 (0/1)
0% Level 2 (0/1)
100% Level 3 (1/1)
0% Level 4 (0/1)
0% Level 5 (0/1)